Benefits of our unique approach
Many late-stage drug trials fail due to an inability to demonstrate clinical efficacy, incurring huge expense, disruption and impact on company value. This is often due to suboptimal study design and recruitment rather than a lack of drug effectiveness.
We are uniquely able to perform high-resolution patient stratification for complex diseases, disentangling the combinations of genes, pathways, and environmental factors that interact to determine a patient’s drug response.
By analyzing the level of drug response as a quantitative trait, we are able to identify the combination of features associated with strong drug responders. These drug response biomarkers can be used with regulators, to refine clinical trial design, and also as complementary diagnostic tools to support new therapeutic product launches.